Evidence-based adverse effects of biologic agents in the treatment of moderate-to-severe psoriasis: Providing clarity to an opaque topic.
about
A Review of Biologic Therapies Targeting IL-23 and IL-17 for Use in Moderate-to-Severe Plaque PsoriasisThe cost-effectiveness of ustekinumab for moderate-to-severe psoriasis.Small molecules and antibodies for the treatment of psoriasis: a patent review (2010-2015).Psoriasiform Drug Eruption Caused by Abatacept: Immunohistochemical Investigation of STAT Signaling.Suppressing IL-36-driven inflammation using peptide pseudosubstrates for neutrophil proteases.
P2860
Evidence-based adverse effects of biologic agents in the treatment of moderate-to-severe psoriasis: Providing clarity to an opaque topic.
description
2015 nî lūn-bûn
@nan
2015年の論文
@ja
2015年論文
@yue
2015年論文
@zh-hant
2015年論文
@zh-hk
2015年論文
@zh-mo
2015年論文
@zh-tw
2015年论文
@wuu
2015年论文
@zh
2015年论文
@zh-cn
name
Evidence-based adverse effects ...... ng clarity to an opaque topic.
@ast
Evidence-based adverse effects ...... ng clarity to an opaque topic.
@en
type
label
Evidence-based adverse effects ...... ng clarity to an opaque topic.
@ast
Evidence-based adverse effects ...... ng clarity to an opaque topic.
@en
prefLabel
Evidence-based adverse effects ...... ng clarity to an opaque topic.
@ast
Evidence-based adverse effects ...... ng clarity to an opaque topic.
@en
P2860
P1476
Evidence-based adverse effects ...... ng clarity to an opaque topic.
@en
P2093
Eric Sorenson
P2860
P304
P356
10.3109/09546634.2015.1027167
P577
2015-04-17T00:00:00Z